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HEPATITIS C TREATMENT IN A DISTRICT HOSPITAL
I N T R O D U C T I O N
Infection by hepatitis C virus (HCV) is a major cause of chronic liver disease all over the world, and the clinical care of patients 
with liver disease associated with HCV infection have raised considerable advancements during last decades. The annual average 
incidence rate is estimated at 6.19 per 100,000 inhabitants in Europe. 1
  O B J E C T I V E S
The aim of this study was the characterization of patients with 
Hepatitis C (HCV) under treatment in a Portuguese District Hospital.
  M E T H O D S
Patients included in this study were followed in a Portuguese District 
Hospital between January 2012 and September 2014, have received 
treatment for HCV and who had at least one infectiology consultation 
in this period. Data were collected from the hospital computer system, 
and patient´s data were collected anonymously, without patient iden-
tification. Data analysis was performed using SPSS v22.0.
  R E S U L T S
Were included in this study 87 patients who met the inclusion crite-
ria, 75% (n=65) were males and 25% (n=22) female, with a mean age 
of 45±10 years. Most patients included in this study were Portuguese, 
resident in the Hospital district and nearby districts. Patients were di-
agnosed with HCV with a mean age of 33±11 years, were followed on 
average for 53.5 years in this Hospital, and were diagnosed with HCV 
on average 12±6.9 years ago. 
Among these patients, 44% (n=38) had genotype 1, 2% (n=2) genotype 
2, 17% (n=15) genotype 3, 13% (n=11) genotype 4 and 24% (n=21) with 
unknown genotype. 
Treatment regimen´s and number of treatments are described in Fig-
ure 1 and Figure 2.
 
Excluding patients who were receiving treatment at the time of data 
collection (September 2014), the average duration of all other treat-
ments performed by patients was 82 months, and most (40%; n=51) of 
treatments performed by patients had a duration from 6 to 9 months.
  DISCUSSION
EASL indicates for patients infected with HCV genotype 1 the treatment 
with a combination of weekly PegIFN-α, daily weight-based ribavirin 
(1000 or 1200 mg in patients <75 kg or  ≥75 kg, respectively), and dai-
ly sofosbuvir (400 mg) for 12 weeks. Additional 12 weeks of Pegylated 
IFN-α and ribavirin should then be administered alone for an addition-
al (total treatment duration 24 weeks) in treatment-naïve and prior 
relapser patients, including cirrhotics, and for an additional 36 weeks 
(total treatment duration 48 weeks) in prior partial and null respond-
ers, including cirrhotics. 2  
For retreatment of HCV-monoinfected or HCV/HIV coinfected patients 
with chronic hepatitis C  who failed to achieve an sustained virological 
response (SVR) on prior antiviral therapy containing ribavirin, the as-
sociation  of PegIFN-α, RBV and either telaprevir or boceprevir. 2
C O N C L U S I O N
From the results, the standard treatment for patients with HCV appears 
to be in accordance with the existing guidelines for the treatment of 
this pathology. 
In the future it would be advisable further analysis and extended to 
other hospitals to assess the degree of compliance with currently exist-
ing guidelines for the treatment of this pathology.
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FIgURE 1: Treatment regimen´s characterisation.
PegIFN: Pegylated Interferon; Ribv: Ribavirin; Boc: Boceprevir; Tel: Telaprevir
FIgURE 2: Number of treatments performed by patient.
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